To understand family caregivers' needs for better preparation and care, this state-of-the-science review examines the effect of caregiving on the health and well-being of caregivers, the efficacy of ...

Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? The following represents disclosure information provided by authors of this manuscript.

Purpose To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer. Methods An update committee reviewed literature published since ...

Real-world usage and outcomes for patients treated with immune checkpoint inhibitors across multiple treatment indications in the Veterans Affairs system. This is an ASCO Meeting Abstract from the ...

To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Median follow-up for treated ...

Cognitive changes associated with cancer and cancer treatments have become an increasing concern. Using breast cancer as the prototype, we reviewed the research from neuropsychological, imaging, ...

Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study The MVAC arm was closed by the ...

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial To investigate the impact of treatment-related ...

This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of RCTs, time frame spanning 2015 to April 2026. An Expert Panel of medical oncology, ...

American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer ...

ASCO journals provide advertisers an extremely cost-effective means for reaching the entire audience of clinical oncologists and hematology malignancy specialists. The publications also reach ...

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT Seven ...